Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure close cooperation with EU nations on licensing new medicines after the transition period.

The United Kingdom published its approach to the Future Relationship with the European Union in February 2020. The approach set outs the UK’s commitments to facilitating trade in medicinal products and supporting high levels of patient safety.

After the transition period, our aim is to make sure patients in the UK are not disadvantaged and continue to be able to access the best and most innovative medicines. We want patients to be reassured that their safety will be protected through the strongest regulatory framework.